BioNTech SE CEO Sahin Ugur sold 76,500 shares in two transactions priced from $102.85 to $103.52 per share. Investors can see that he retained 781,709 BioNTech shares after the sales, while the transactions occurred on 2026-09-03 and 2026-09-04.
Key Highlights
- The transactions were executed at prices ranging from $102.85 to $103.52 per share.
- Sahin Ugur retained 781,709 BioNTech SE shares after the sales.
- Both transactions occurred on 3 September 2026 and 4 September 2026 under code S.
BioNTech SE (NASDAQ: BNTX) Chief Executive Officer Sahin Ugur sold 76,500 shares across two transactions.
Two Transactions Priced Up to $103.52
Ugur’s two transactions were recorded on 3 September 2026 and 4 September 2026. Prices ranged from $102.85 to $103.52 per share across the activity. The reported sale count covers both entries, while the price range identifies the consideration attached to each share sold.
These were separate transactions, not a single reported sale.
The ownership figure represents the remaining share position linked to the reported activity. It reflects a disclosed sale alongside continuing ownership by BioNTech SE’s chief executive.
FAQs
Q: How many BioNTech shares did Sahin Ugur sell?
A: Sahin Ugur sold 76,500 BioNTech SE shares across two transactions. The sales were priced between $102.85 and $103.52 per share.
Q: What was the impact of Sahin Ugur’s BioNTech share sale?
A: The transactions left Sahin Ugur with 781,709 BioNTech SE shares. The information shows a completed insider sale alongside continuing ownership.
Q: When did the BioNTech CEO sell shares?
A: The two transactions took place on 3 September 2026 and 4 September 2026. Both used transaction code S, indicating open-market sales in insider transaction reporting.
Download Free Report – Explore 3 Stock Ideas & Industry Insights
Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.
All investments involve risk—consider independent advice before making any investment decisions.
View 3 Research Reports
Disclaimer:
Kalkine Equities LLC, with Delaware File Number 4697384, Foreign Qualification Registration in California File Number 202109211078, and Texas File Number 805521396, is authorized to provide general advice only. The information on https://kalkine.com/ does not take into account any of your investment objectives, financial situation or needs. You should consider the appropriateness of advice taking into account your own objectives, financial situation and needs and seek independent financial advice before making any financial decisions. The link to our Terms and Conditions and Privacy Policy has been provided for your reference. On the date of publishing the reports (mentioned on the website), employees and/or associates of Kalkine do not hold positions in any of the stocks covered on the website. These stocks can change any time and readers of the reports should not consider these stocks as advice or recommendations later.